Prioritizing the risk of cervical cancer: findings from the SCCUT Multicentre Initiative.

Q3 Medicine
Gabriel Marian Saveliev, Valentin Nicolae Varlas, Madalina Piron-Dumitrascu, Nicolae Suciu
{"title":"Prioritizing the risk of cervical cancer: findings from the SCCUT Multicentre Initiative.","authors":"Gabriel Marian Saveliev, Valentin Nicolae Varlas, Madalina Piron-Dumitrascu, Nicolae Suciu","doi":"10.25122/jml-2025-0100","DOIUrl":null,"url":null,"abstract":"<p><p>Cervical cancer (CC) remains a significant global health burden, ranking eighth in incidence and ninth in cancer-related mortality among women worldwide. Persistent infection with high-risk human papillomavirus (HPVhr) is the primary etiological factor in CC development. The SCCUT program in Romania was designed to enhance access to primary screening and assess HPVhr prevalence among women aged 25-65 years in the South-Muntenia region. Between August 2022 and November 2023, a total of 36,813 women were enrolled in the SCCUT program after providing informed consent. Based on age, participants underwent either a Pap test and/or HPVhr testing. Clinical and demographic data-including age, hormonal status, intrauterine device (IUD) use, presence of leucorrhea, and history of cervical interventions-were collected via structured questionnaires. HPVhr testing was performed using the AmpFire<sup>®</sup> HPV Screening system and processed in the lead partner laboratory. Of the total cohort, 12.5% (<i>n</i> = 4,588) tested positive for HPVhr. HPVhr positivity was significantly associated with younger age (mean 45.12 ± 9.21 years vs. 46.28 ± 8.56 years; <i>P</i> < 0.001) and cyclic hormonal status (<i>P</i> < 0.001). No statistically significant associations were found between HPVhr status and IUD use, presence of leucorrhea, or prior cervical interventions (biopsies or cauterizations). The SCCUT program confirms the critical role of HPVhr in cervical carcinogenesis and supports its use as a first-line screening tool. These findings highlight the importance of implementing widespread primary HPVhr testing, particularly in underserved populations. Increasing public awareness, improving HPV vaccination rates, and expanding access to early detection programs remain essential for effective cervical cancer prevention in Romania and globally.</p>","PeriodicalId":16386,"journal":{"name":"Journal of Medicine and Life","volume":"18 6","pages":"590-593"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314842/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicine and Life","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25122/jml-2025-0100","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Cervical cancer (CC) remains a significant global health burden, ranking eighth in incidence and ninth in cancer-related mortality among women worldwide. Persistent infection with high-risk human papillomavirus (HPVhr) is the primary etiological factor in CC development. The SCCUT program in Romania was designed to enhance access to primary screening and assess HPVhr prevalence among women aged 25-65 years in the South-Muntenia region. Between August 2022 and November 2023, a total of 36,813 women were enrolled in the SCCUT program after providing informed consent. Based on age, participants underwent either a Pap test and/or HPVhr testing. Clinical and demographic data-including age, hormonal status, intrauterine device (IUD) use, presence of leucorrhea, and history of cervical interventions-were collected via structured questionnaires. HPVhr testing was performed using the AmpFire® HPV Screening system and processed in the lead partner laboratory. Of the total cohort, 12.5% (n = 4,588) tested positive for HPVhr. HPVhr positivity was significantly associated with younger age (mean 45.12 ± 9.21 years vs. 46.28 ± 8.56 years; P < 0.001) and cyclic hormonal status (P < 0.001). No statistically significant associations were found between HPVhr status and IUD use, presence of leucorrhea, or prior cervical interventions (biopsies or cauterizations). The SCCUT program confirms the critical role of HPVhr in cervical carcinogenesis and supports its use as a first-line screening tool. These findings highlight the importance of implementing widespread primary HPVhr testing, particularly in underserved populations. Increasing public awareness, improving HPV vaccination rates, and expanding access to early detection programs remain essential for effective cervical cancer prevention in Romania and globally.

Abstract Image

优先考虑宫颈癌的风险:来自SCCUT多中心倡议的发现。
子宫颈癌仍然是一个重大的全球健康负担,在全世界妇女的发病率中排名第八,在与癌症有关的死亡率中排名第九。持续感染高危人乳头瘤病毒(HPVhr)是CC发展的主要病因。罗马尼亚SCCUT项目的目的是提高初级筛查的可及性,并评估南黑山地区25-65岁妇女的HPVhr流行情况。在2022年8月至2023年11月期间,共有36813名女性在提供知情同意后参加了SCCUT项目。根据年龄,参与者接受巴氏试验和/或HPVhr测试。临床和人口统计数据,包括年龄、激素状况、宫内节育器(IUD)使用、白带存在和宫颈干预史,通过结构化问卷收集。HPVhr检测使用AmpFire®HPV筛查系统进行,并在主要合作伙伴实验室进行处理。在整个队列中,12.5% (n = 4588)的HPVhr检测呈阳性。HPVhr阳性与低龄相关(平均45.12±9.21岁∶46.28±8.56岁;P < 0.001)和周期激素状态(P < 0.001)。HPVhr状态与宫内节育器使用、白带存在或既往宫颈干预(活检或烧灼)之间没有统计学上的显著关联。SCCUT项目证实了HPVhr在宫颈癌发生中的关键作用,并支持将其作为一线筛查工具。这些发现突出了广泛实施初级HPVhr检测的重要性,特别是在服务不足的人群中。提高公众意识,提高HPV疫苗接种率,扩大早期发现规划的可及性,对于罗马尼亚和全球有效预防宫颈癌仍然至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Medicine and Life
Journal of Medicine and Life Medicine-Medicine (all)
CiteScore
1.90
自引率
0.00%
发文量
202
期刊介绍: The Journal of Medicine and Life publishes peer-reviewed articles from various fields of medicine and life sciences, including original research, systematic reviews, special reports, case presentations, major medical breakthroughs and letters to the editor. The Journal focuses on current matters that lie at the intersection of biomedical science and clinical practice and strives to present this information to inform health care delivery and improve patient outcomes. Papers addressing topics such as neuroprotection, neurorehabilitation, neuroplasticity, and neuroregeneration are particularly encouraged, as part of the Journal''s continuous interest in neuroscience research. The Editorial Board of the Journal of Medicine and Life is open to consider manuscripts from all levels of research and areas of biological sciences, including fundamental, experimental or clinical research and matters of public health. As part of our pledge to promote an educational and community-building environment, our issues feature sections designated to informing our readers regarding exciting international congresses, teaching courses and relevant institutional-level events.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信